Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan Williams

Showing results (151-160 of 417) with videos related to

Pageof 42
Sort By:
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|March 27, 2019
Exercise and Cognitive Training as a Strategy to Improve Neurocognitive Outcomes in Heart Failure: A Pilot StudyRebecca A Gary, Sudeshna Paul, Elizabeth Corwin, et al.
European Heart Journal|April 20, 2020
Chronotherapy in hypertension: the devil is in the detailsGreg Guthrie, Neil Poulter, Thomas Macdonald, et al.
European Heart Journal|March 26, 2019
Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY RegistryFelix Mahfoud, Michael Böhm, Roland Schmieder, et al.
American Journal of Nephrology|September 4, 2018
Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER StudyRajiv Agarwal, Patrick Rossignol, Dahlia Garza, et al.
Diabetes, Obesity & Metabolism|September 6, 2019
Intensive glucose-lowering and the risk of vascular events and premature death in patients with decreased kidney function: The ADVANCE trialToshiaki Ohkuma, Sophia Zoungas, Min Jun, et al.
Journal of Occupational and Environmental Medicine|October 30, 2013
Pesticide risk perception and biomarkers of exposure in Florida female farmworkersJennifer D Runkle, J Antonio Tovar-Aguilar, Eugenia Economos, et al.
Hypertension (Dallas, Tex. : 1979)|December 11, 2013
Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trialJohn Chalmers, Hisatomi Arima, Mark Woodward, et al.
Lancet (London, England)|September 20, 2019
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trialRajiv Agarwal, Patrick Rossignol, Alain Romero, et al.
Plos One|September 6, 2018
Time spent at blood pressure target and the risk of death and cardiovascular diseasesSheng-Chia Chung, Mar Pujades-Rodriguez, Bram Duyx, et al.
Hypertension (Dallas, Tex. : 1979)|September 9, 2024
Resistant Hypertension and Mortality: An Observational Cohort StudyAlejandro de la Sierra, Luis M Ruilope, Natalie Staplin, et al.
Pageof 42

Showing results (151-160 of 417) with videos related to

Sort By:
Pageof 42
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|March 27, 2019
Exercise and Cognitive Training as a Strategy to Improve Neurocognitive Outcomes in Heart Failure: A Pilot StudyRebecca A Gary, Sudeshna Paul, Elizabeth Corwin, et al.
European Heart Journal|April 20, 2020
Chronotherapy in hypertension: the devil is in the detailsGreg Guthrie, Neil Poulter, Thomas Macdonald, et al.
European Heart Journal|March 26, 2019
Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY RegistryFelix Mahfoud, Michael Böhm, Roland Schmieder, et al.
American Journal of Nephrology|September 4, 2018
Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER StudyRajiv Agarwal, Patrick Rossignol, Dahlia Garza, et al.
Diabetes, Obesity & Metabolism|September 6, 2019
Intensive glucose-lowering and the risk of vascular events and premature death in patients with decreased kidney function: The ADVANCE trialToshiaki Ohkuma, Sophia Zoungas, Min Jun, et al.
Journal of Occupational and Environmental Medicine|October 30, 2013
Pesticide risk perception and biomarkers of exposure in Florida female farmworkersJennifer D Runkle, J Antonio Tovar-Aguilar, Eugenia Economos, et al.
Hypertension (Dallas, Tex. : 1979)|December 11, 2013
Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trialJohn Chalmers, Hisatomi Arima, Mark Woodward, et al.
Lancet (London, England)|September 20, 2019
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trialRajiv Agarwal, Patrick Rossignol, Alain Romero, et al.
Plos One|September 6, 2018
Time spent at blood pressure target and the risk of death and cardiovascular diseasesSheng-Chia Chung, Mar Pujades-Rodriguez, Bram Duyx, et al.
Hypertension (Dallas, Tex. : 1979)|September 9, 2024
Resistant Hypertension and Mortality: An Observational Cohort StudyAlejandro de la Sierra, Luis M Ruilope, Natalie Staplin, et al.
Pageof 42